The latest announcement is out from Vor Biopharma ( (VOR) ).
Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical development and extend cash runway through 2025. The transaction involves significant stakeholders, including Reid Hoffman and RA Capital Management, and is expected to bolster Vor Bioâs efforts in advancing its clinical trials for cancer therapies, with updated data announcements anticipated in 2025.
More about Vor Biopharma
Vor Bio is a clinical-stage cell and genome engineering company focused on transforming the treatment of blood cancers by engineering hematopoietic stem cells to enhance targeted therapies post-transplant.
YTD Price Performance: -62.76%
Average Trading Volume: 555,431
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $57.55M
Learn more about VOR stock on TipRanksâ Stock Analysis page.
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel
